What are the best treatments for 22q13 deletion / Phelan-McDermid Syndrome?

TL;DR: There is currently no single cure for 22q13 deletion / Phelan-McDermid Syndrome, so treatment is focused on a multidisciplinary, symptom-specific approach to improve quality of life. Management typically involves early intervention therapies, such as speech and occupational therapy, alongside targeted pharmacological support for behavioral challenges and epilepsy.

What are the primary treatment goals for Phelan-McDermid Syndrome?

Because 22q13 deletion / Phelan-McDermid Syndrome (PMS) presents with a wide spectrum of clinical features, including global developmental delay, absent or delayed speech, and autism spectrum disorder, treatment must be highly personalized. The primary goal is to maximize the individual's functional independence through a combination of educational, behavioral, and medical interventions. Because 35 members of the DiseaseMaps.org community live with this condition, we recognize that every patient’s journey is unique; what works for one individual may differ significantly for another depending on the specific size and location of the genetic deletion.

Which therapies and specialists are essential for care?

A multidisciplinary care team is crucial for managing 22q13 deletion / Phelan-McDermid Syndrome. Care is usually coordinated by a clinical geneticist or a developmental pediatrician, with support from a variety of specialists. Effective management generally includes the following non-pharmacological therapies:

• Speech and Language Therapy: Often the most critical intervention, focusing on alternative communication methods (AAC) for those with severely delayed or absent speech.


• Occupational Therapy: Aimed at improving sensory processing and daily living skills.


• Physical Therapy: Essential for addressing hypotonia (low muscle tone) and motor delays commonly seen in early childhood.


• Applied Behavior Analysis (ABA): Often utilized to manage challenging behaviors and improve social engagement.

How is the condition managed pharmacologically?

There are no medications that treat the underlying genetic cause of 22q13 deletion / Phelan-McDermid Syndrome. However, physicians may prescribe medications to manage specific co-occurring conditions. For example, if a patient experiences seizures, which occur in approximately 40% to 75% of individuals with the syndrome, anti-epileptic drugs (AEDs) such as levetiracetam (Keppra) or valproic acid (Depakote) may be used. For sleep disturbances or severe behavioral challenges, clinicians might trial medications like melatonin or, in specific cases, atypical antipsychotics, though these must be monitored closely for side effects.

Are there emerging treatments or clinical trials?

Research into 22q13 deletion / Phelan-McDermid Syndrome is rapidly evolving. Current clinical trials are investigating the role of the SHANK3 gene, which is typically deleted or disrupted in this syndrome. Researchers are exploring pharmacological agents that may enhance synaptic function or modulate neurotransmitter pathways to address the neurological manifestations of the syndrome. Families interested in participating in research should consult with their geneticist to identify active clinical trials registered on ClinicalTrials.gov.

Next steps

• Consult with a developmental pediatrician or clinical geneticist to establish a comprehensive care plan.


• Connect with the DiseaseMaps.org community to share experiences and learn from others managing the complexities of 22q13 deletion / Phelan-McDermid Syndrome.


• Register with the Phelan-McDermid Syndrome Foundation (PMSF) to access patient registries and the latest clinical guidance.


• Maintain a detailed medical log to track the effectiveness of therapies and any new symptoms, such as the onset of seizures.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; all treatment decisions must be made in consultation with a qualified healthcare professional.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Phelan-McDermid Syndrome.


• Orphanet: 22q13.3 deletion syndrome.


• Phelan-McDermid Syndrome Foundation (PMSF): Clinical management guidelines.


• OMIM (Online Mendelian Inheritance in Man): #606232 Phelan-McDermid Syndrome.